Prospective clinical study to confirm and extend the correlation between HSD11B1 polymorphisms, bone mineral density, and cortisol metabolism in patients with osteoporosis

Prospective clinical study to confirm and extend the correlation between HSD11B1 polymorphisms, bone mineral density, and cortisol metabolism in patients with osteoporosis - OsteoGene

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00016601

Enrollment

500

Registered

2020-04-30

Start date

2017-12-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M80 M81 M82 E10 E11 E12 E13 E14 E78 F32 F33 F34

Interventions

Group 1: To analyse the individual osteoporosis risk, all examinations recommended by DVO will be performed, including measurements of bone mineral density by Dual-Energy-Xray-absorptiometry (DXA) and

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: > 20% increased 10-year fracture risk

Exclusion criteria

Exclusion criteria: glucocorticoid therapy

Design outcomes

Primary

Measure	Time frame
Association of HSD11B1 SNP genotypes with BMD (bone mineral density) and PDC (post dexamethasone cortisol)	—

Secondary

Measure	Time frame
Muscle function: Timed-up and go, chair rising, grip strength measurement; Metabolism: LDL cholesterol, HbA1c; Depression: Questionnaire (HADS Score); Bone quality: Trabecular Bone Score (TBS)	—

Countries

Germany

Contacts

Public ContactHeide Siggelkow

MVZ Endokrinologikum Göttingen

heide.siggelkow@amedes-group.com055163374633

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026